As the number of FDA-approved monoclonal antibodies continues to grow,
biopharmaceutical companies are looking to shrink the 10 or more years it
usually takes for a biologic candidate to progress from drug discovery to
regulatory approval.
Curia leverages proprietary technology and creative process engineering to
find the most efficient route to GMP manufacturing of clinical phase drug
substance in as little as one year.
Increase speed, reduce risk and maintain quality by partnering with a
CDMO that has a comprehensive program for moving from discovery to
clinical batches of a new biologic.
© 2023 Curia Global, Inc. All rights reserved. The trade/service marks used herein are the property of Curia Global, Inc. or their respective owners. Use of the ® symbol
indicates that the mark has been registered in at least the United States. Use of the TM or SM symbol indicates that the mark is in use in at least the United States.
›
Rapid antibody discovery process
›
Cell line development using
CHO-GSN℠ platform
›
Drug product formulation
development and manufacturing
›
Specialization in First-to-Human
manufacturing support
TO
LEARN
MORE,
DOWNLOAD
OUR
WHITE
PAPER.
Proven expertise in monoclonal antibody
discovery and development
